BPC-157 — Gastric pentadecapeptide / pleiotropic cytoprotective peptide

BPC-157 is the most clinically used peptide in sports medicine and integrative practice with the least regulatory oversight. The evidence gap is stark: hundreds of animal studies, zero completed Phase 3 human RCTs. The human IBD trials (PL 14736 enema formulation) were encouraging but not Phase 3 level. The oral bioavailability documentation is clinically relevant — the gastric juice origin protein suggests oral stability, but systemic oral bioavailability for musculoskeletal indications remains unproven. Practitioners should be transparent with patients: this is a C-grade compound with compelling preclinical data but no human registration trial. The pro-angiogenic mechanism warrants caution in patients with any malignancy history.

نظرة عامة

هذه الصفحة جزء من مكتبة المركّبات المُصنَّفة بالأدلة في Hormonaly. جميع الادعاءات السريرية مرتبطة بمصادر علمية مُحكَّمة عبر خط أنابيب التحقق المزدوج للاستشهادات.

فئة المركّب

Gastric pentadecapeptide / pleiotropic cytoprotective peptide

آلية العمل

Synthetic 15-amino acid peptide derived from human gastric juice protein BPC. Pleiotropic mechanism: (1) Upregulates nitric oxide (NO) synthesis — primary driver of angiogenesis, vaspdilation, and tissue perfusion; (2) Activates FAK (focal adhesion kinase) and paxillin pathways promoting cytoskeletal reorganization and cell migration; (3) Upregulates GH receptor expression — sensitizes tissues to growth hormone signal; (4) Inhibits inflammatory cytokines (TNF-α, IL-6) via NF-κB suppression; (5) Directly interacts with dopaminergic, GABAergic, and serotonergic systems. Remarkably stable in gastric acid (unlike most peptides) — oral bioavailability is notable and distinguishes it from other peptides. Animal models show consistent healing across tendon, ligament, muscle, GI tract, bone, and neural tissue.

الوضع التنظيمي

Not FDA-approved; not scheduled; compounded peptide available through compounding pharmacies; IND studies conducted (PL 14736 by Pliva)

مستوى الأدلة

Moderate preclinical, limited human — Extensive animal RCT data across multiple injury models consistently shows healing acceleration; Phase 1 human trials (PL-10, PL 14736 for IBD) have been conducted; NO completed Phase 3 RCTs; therefore C-grade